Elizabeth Kwo, MD, MBA, MPH, is the deputy chief clinical officer, Anthem Blue Cross Blue Shield, Boston, Massachusetts. Kwo is a faculty lecturer at Harvard Medical School and physician entrepreneur.
Remote patient monitoring has applicability to many scenarios, including urgent care uses; long-term monitoring to help keep patients with cancer out of the hospital, by monitoring the effects of oncology treatment at home; and even voice monitoring to check for altered mental status. And those are just a few, said Elizabeth Kwo, MD, MBA, MPH, the deputy chief clinical officer at Anthem BlueCross BlueShield, who took part in the panel discussion on remote patient monitoring during Patient-Centered Oncology Care® (PCOC).
How can payers use remote patient monitoring to advance value-based care, particularly in oncology?
KWO: There are multiple ways right now, in terms of how payers are leveraging digital devices—it’s called the Internet of Things. Remote patient monitoring can consist of something called TIDO [digital package and website].1 Not only are there certain devices that allow you to connect with a doctor, but [with] certain devices you can show the doctor, say, your mouth and your ear. There are also other ways to speak to the doctor and urgent care in the setting of your own home.
Also available is long-term monitoring; instead of in the moment of care with the doctor, you’re actually getting monitored with the device. Of course, many things allow that, like wearables—[simply], things that you can wear that monitor [functions], from your heart rate to your temperature. Let’s say in a postdischarge situation, if someone’s on chemotherapy, [a device can tell] whether they spike a fever or if they’re dehydrated. For instance, electrolytes—there are ways to now monitor that remotely. There are also different ways [of handling] when a patient is asking questions. We now have something called voice biomarkers, which can indicate, [when a trained person] listens to them, how a patient is doing, just by looking at speech patterns they use in the home—whether or not they may have signs of, let’s say, delirium or dementia. So, a lot right now is moving ahead within the ecosys tem of the health care space.
Reference
TIDO, Inc. website. Accessed October 12, 2021. https://tidoinc. com/
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Cardiovascular Magnetic Resonance Highlights Sex-Specific Characteristics in Aortic Stenosis
February 19th 2025This multicenter study sheds more light on sex-based differences in aortic stenosis (AS) and argues the benefits of using cardiovascular magnetic resonance (CMR) to assess sex-based risks in AS.
Read More